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Germline mutations in BRCA1 and BRCA2 
genes account for genetic predisposition and in-
creased risk of breast and ovarian cancers [1]. 
Most hereditary breast and ovarian cancers are 
due to highly penetrant germline BRCA muta-
tions which are inherited in an autosomal domi-
nant fashion. In these patients, there are fre-
quently several generations of women affected 
with breast cancer (often premenopausal) and in 
some families’ ovarian cancer as well. In addi-
tion, other BRCA-associated malignancies, such 
as prostate, male breast, and pancreatic cancer 
may also be observed [2]. The Hereditary Breast 
and Ovarian Cancer (HBOC) syndrome is caused 
by loss-of-function mutations in the BRCA1 and 
BRCA2 genes and explains approximately 16% 
of inherited breast cancers [3]. Germline delete-
rious mutations in BRCA1 (17q11) and BRCA2 
(13q12–q13) are associated with a substantially 
increased risk of breast cancer as compared with 
the general population, with a cumulative lifetime 
breast cancer risk of 46–60% in BRCA1 carriers 
and 43–55% in BRCA2 carriers [4–6]. These mu-
tations have a prevalence of 5–10% in the gen-
eral breast cancer population and up to 10–20% 
in those patients with triple‐negative breast cancer 
(TNBC) [7–9], and they have been suggested to be 
responsible for approximately half of all hereditary 
breast and ovarian cancer cases [10]. Couch et al. 
1996 reported a total of 254 BRCA1 mutations, 132 
(52%) of which were unique. These represented 
mutations entered into a database established by 
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background: the incidence of breast cancer is growing rapidly worldwide (1.7 million new cases and 600,000 deaths per year). 
Moreover, about 10% of breast cancer cases occur in young women under the age of 45.  the aim of the study was to report a 
rare case of Brca1-mutated breast cancer in a young patient with multiple affected relatives. Breast cancer is due to a genetic 
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the Breast Cancer Information Core (BIC). A to-
tal of 221 (87%) of all mutations or 107 (81%) of 
the unique mutations are small deletions, inser-
tions, nonsense point mutations, splice variants, 
and regulatory mutations that result in truncation 
or absence of the BRCA1 protein. A total of 11 
disease-associated missense mutations (5 unique) 
and 21 variants (19 unique) as yet unclassified as 
missense mutations or polymorphisms had been 
detected. Thirty-five independent benign poly-
morphisms had been described. The most com-
mon mutations were 185delAG (113705.0003) and 
5382insC (113705.0018), which accounted for 30 
(11.7%) and 26 (10.1%), respectively, of all the 
mutations [11]. Consistent with the role of BRCA1 
and BRCA2 in DNA repair, germline mutations 
in these genes lead to impaired homologous re-
pair of chromosomal double strand breaks, with at 
least a five‐fold reduction in DNA double strand 
break repair [12]. This, subsequently, predisposes 
patients to chromosomal instability and leads to 
unique treatment opportunities, including sensi-
tivity to DNA‐damaging agents, ionizing radia-
tion, and poly (ADP‐ribose) polymerase (PARP) 
inhibitors [13–15]. Multiple studies have evalu-
ated neoadjuvant chemotherapy in BRCA‐mutated 
breast cancers, specifically focusing on pathologic 
complete response (pCR) rates, a known surrogate 
for clinical efficacy and outcome. A larger observa-
tional study evaluating pCR rates in BRCA1‐posi-
tive breast cancer patients found high rates of pCR 
in patients receiving neoadjuvant cisplatin (pCR in 
10 of 12 patients, 83%), substantially higher than 
pCR rates in BRCA1‐mutated breast cancer pa-
tients treated with cyclophosphamide, methotrex-
ate, and fluorouracil (CMF, 7%); doxorubicin and 
docetaxel (AT, 8%); or doxorubicin and cyclophos-
phamide with and without fluorouracil (FAC, 22%) 
[16]. Patients with invasive breast cancer caused 
by hereditary breast cancer syndromes constitute 
a unique patient population with individualized, 
rationally targeted systemic treatment options. The 
most common syndrome leading to an increased 
risk of breast cancer, BRCA-related breast cancer 
syndrome, involves harmful germline mutations 
in BRCA1 and BRCA2. These patients are par-
ticularly sensitive to DNA damaging agents such 
as platinum agents, as well as to PARP inhibitors, 
which, by blocking the formation of ADP-ribose 
polymers at the site of single-strand breaks, pre-
vent recruitment of DNA damage repair [17]. 
Other unique therapies tested in BRCA-mutated 
invasive breast cancer patients include trabectin, 
given preclinical evidence suggesting specific ac-
tivity against intact metastatic breast cancer with 
excisional nucleotide repair or homologous repair 
by recombination [18], and lurbinectin, which in-
duces double-strand breaks resulting in activity 
against platinum-resistant tumors and cell lines 
deficient in homologous recombination [19].
We report a rare case of BRCA1-mutated breast 
cancer in a young patient with multiple affected 
relatives.
case presentation
Patient A., 29 years old, Asian (Kazakh), house-
wife. Diagnosed with carcinoma of the left breast 
STIIIAT2N2M0. Condition after neoadjuvant che-
motherapy (neo-PCT) + bilateral radical mastec-
tomy + radiation therapy.
In September 2016, while breast-feeding the 
fourth child, she independently found a mass in 
the left breast. Ultrasonography of the mammary 
glands in one month revealed nodulation with size 
26 × 22 × 17 mm. Further PET-CT (Fig. 2) was 
performed and a conclusion was: Abnormal growth 
of metabolic activities observed in the lower part of 
the left breast and lymph nodes of the left axillary 
region compatible with malignant structure. Local 
examination at the time of diagnosis: In the left 
breast in the lower quadrant — a dense, inactive 
tumor with the size 3 × 3 cm and in the left axil-
lary region lymph node 1 × 1 cm. Right breast and 
lymph nodes without pathology. Trepan biopsy of 
the left breast lump was performed. The result of 
histology was invasive ductal carcinoma of nonspe-
cific type (Fig. 1).
Figure 1. pet-ct of the mammary glands
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results
The result of IGH — RE-0B, RP — 2B, HER2Neo 
— negative, Ki 67 — 60%. The patient received 4 
courses of neoadjuvant polichemotherapy (NPCh) 
with the FEC scheme (dexamethasone 12 mg I/V 
drip to 100 ml physiological saline solution on day 
1, epirubicin 138 mg I/V drip to 100 ml physiologi-
cal saline solution on day 1, fluorouracil 690 mg 
I/V drip on day 1, cyclophosphamide 690 mg I/V 
drip physiological saline solution on day 1). Then 
the patient received 12 courses of paclitaxel 110 
mg I/V per 500 ml of physiological saline solution. 
After treatment, there was regression. Heredity is 
burdened. Her older sister died of ovarian cancer 
at the age of 43. Her father died of lung cancer at 
the age of 51. Pregnancy — 4; childbirth — 4; abor-
tion — 0.
Considering the family history, the patient un-
derwent medical genetic counseling with informed 
consent. Peripheral whole blood was taken in 
a volume of 10 ml. Extraction of DNA from 100 μl 
of peripheral blood was performed using a set of 
reagents “Proba-GS-Genetics” (NPO DNA-Tekh-
nologiya, Russia), according to the manufacturer’s 
instructions.
Genotyping was performed by real-time poly-
merase chain reaction (PCR) using the BRCA On-
coGenetics kit (including 8 mutations in the BRCA1 
genes (mutations 185delAG, 4153delA, 5382insC, 
3819delGTAAA, 3875delGTCT, 300T> G (Cysdel-
61Gly), 2080 BRCA2 (mutation 6174delT) accord-
ing to the manufacturer’s instructions. PCR was 
performed using a DTprime detecting amplifier 
(NPO DNA-Tekhnologiya, Russia).
The study was carried out in a scientific mo-
lecular genetic laboratory at the Marat Ospanov 
West Kazakhstan Medical University . Conclusion: 
the study of the DNA sample revealed: heterozy-
gous replacement in the BRCA1 gene mutation 
5382incS. The patient after chemotherapy treat-
ment had bilateral subcutaneous mastectomy with 
axillary lymph node dissection. The result of the fi-
nal histology — fibrosis in both mammary glands, 
metastases of the axillary lymph nodes were re-
vealed. Then, a postoperative course of radiation 
therapy on the linear accelerator “Trubeam” on 
the left breast and the zone of the regional lymph 
node was given SOD-46 Gr. when the ROD was 
2.0 Gr. Considering the presence of a gene muta-
tion (5382incS) in the patient and her family his-
tory, medical and genetic counseling of relatives 
(mother, brother, sisters and their adult children) 
was carried out, informed consent was obtained 
from all members of her family. 8 relatives were ex-
amined, in whom 3 mutations were identified. The 
analysis revealed a similar mutation 5382incS in 
her own older brother (42 years old) and her own 
daughter (17 years old), her own second older sis-
ter (37 years old). The eldest sister, J., 1975 year of 
Figure 2. the pedigree of patient under study
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birth. In October of 2015 she was diagnosed with 
carcinoma of the ovary STIIIT3N1M0. In Novem-
ber 2018 molecular genetic study of mutation of 
BRCA1, BRCA2 genes was carried out. Conclusion: 
in the studied sample in exon 20 of the BRCA1 
gene detected 5382incS mutation in a heterozy-
gous state. Despite the treatment, the therapy was 
unsuccessful, the patient died on 28.11.2018 at the 
age of 43 years.
Native second eldest sister, A. born in 1981. Dis-
covered BRCA1 mutation 5382incS. She was ex-
amined. According to mammography — BI-RADS 
M2-L2, breast ultrasound — the lump of the left 
breast, the size of 1.5–2 cm. A puncture of the mass 
was done, the result of cytology without atypia. 
Ultrasound of the pelvis — without pathology. The 
patient is under the supervision of oncologists.
Older brother (G.) born in 1976. BRCA1 muta-
tion 5382 incS was detected. At the time of the 
medical examination he had no complaints. Tu-
mor marker PSA — 0.3 ng\ml. MRI of the prostate 
— MRI picture is typical for nodulation of the right 
prostate. The patient is under observation.
Niece (brother’s daughter) — born in 2002, was 
similarly examined in January 2019. BRCA1 muta-
tion 5382 insc was detected. According to ultra-
sound of the pelvis: no structural changes. Breast 
ultrasound — in the right breast of the upper outer 
quadrant hypoallergenic formation of 2.0 × 1.2 cm, 
similar to the left breast 2.9 × 1.9 cm. Fibroad-
enoma of both mammary glands. A puncture of 
the formation of mammary glands was performed. 
The result of cytology without atypia. The patient is 
under observation. 
The pedigree was based on the interview of the 
patient under study; it is impossible to determine 
the genetic status of deceased ancestors (Fig. 2).
In the presented case, the patient has luminal 
B type breast cancer. According to TCGA, breast 
cancer luminal B is characterized by a high TP53 
mutation rate (29%) and a slightly lower muta-
tion rate of the PIK3CA catalytic subunit alpha 
(29%). The main characteristics of genomic, clini-
cal and proteomic subtypes are as follows: mRNA 
expression — lower ER cluster; high proliferation; 
DNA methylation — hypermethylated phenotype 
for a subset; protein expression — less estrogen 
signaling; high FOXM1 and MYC; reactive RPPA 
subtypes; DNA mutations — TP53 (32%); PIK3CA 
(32%); MAP3K1 (5%) [20].
Discussion
Unlike sporadic cancers, up to 10% of all cancers 
are due to hereditary genetic defects. Hereditary 
cancer was first described by doctors-researchers 
A. Warthin and H. Lynch, who detected families 
predisposed to cancer, which, in turn, led to the 
identification of hereditary cancer syndromes [20]. 
A number of affected families will inherit one al-
lele of the mutated predisposition gene, called the 
“germ line mutation”, which is hidden in every cell 
of the body. As a result, hereditary cancers are char-
acterized by 1) early onset cancer, often younger 
than 50 years at diagnosis compared to an average 
age of 60 years in the general population, 2) family 
history of cancer across generations in which can-
cer types correspond to the tumor spectrum of the 
syndrome, as confirmed in this clinical case [22]. 
Our data are consistent with the research of A. Ra-
thore who showed that mutated BRCA carcinoma 
is found in young people with a family history of 
the disease [23]. In our case, four out of six chil-
dren were found to have a mutation in the BRCA1 
gene, and two generations were found to have this 
mutation. One family member died of ovarian can-
cer. This patient developed the disease at early age. 
Other family members have a benign formation. 
However, at the insistence of the family members 
themselves, we are not talking about the preventive 
removal of organs. Therefore, they are under careful 
supervision of oncologists.
Only a relatively small proportion of breast 
cancers can be explained by the presence of ge-
netic mutations with high penetrance, such as the 
BRCA1 and BRCA2 genes [24]. Together with mu-
tations in genes of intermediate penetrance, such as 
ATM, BARD1, PALB2, and CHECK2, they explain 
20–25% of the risk of breast cancer, leaving a sig-
nificant proportion of heredity that remains to be 
explained by variants with low penetrance [25]. 
Undoubtedly, ongoing research into families with 
multiple cancer-affected members will lead to the 
identification of other variants in these genes that 
also predispose to breast cancer [26].
Many genes for different populations have been 
thoroughly studied [27]. The identified BRCA1 
5382insC mutation in our patient was identified at 
a frequency of 0.13% in the Jewish population [28], 
also found in the population of Austria, Slovenia, 
Germany, Czech Republic, Greece, Denmark, Po-
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land, Latvia, Lithuania, Belarus and Russia [10]. In 
Kazakhstan, according to the work of the author B. 
Apsalikov, out of 250 women, a similar mutation 
was found in 23. This indicates the occurrence of 
this mutation in our population [29]. But all this 
still requires further large-scale research.
In addition, molecular genetic testing is becom-
ing an important tool for predicting drug reactions, 
as new target therapeutic agents, such as poly inhib-
itors, appear and platinum-based sensitivity is re-
ported [30]. In our case, the patient was prescribed 
12 courses of paclitaxel and there was a significant 
regression of the tumor, which was confirmed by 
the instrumental study.
Given that BRCA1 and BRCA2 were identified 
more than 20 years ago, preventive mastectomy 
remains the gold standard, mutation carriers have 
strong preferences for chemoprophylaxis [31]. The 
patient underwent bilateral subcutaneous mastec-
tomy with lymph node dissection. 
The Cancer Genome Atlas (TCGA), a landmark 
program in the genomics of cancer, has molecu-
larly characterized over 20,000 primary cancers and 
matched normal samples covering 33 cancers. This 
collaborative effort between the National Cancer 
Institute and the National Human Genome Re-
search Institute began in 2006 and brought together 
researchers from different disciplines and multiple 
institutions.
Over the next ten years, TCGA generated over 
2.5 petabytes of genomic, epigenomic, transcrip-
tomic, and proteomic data. Data that have already 
improved our ability to diagnose, treat, and prevent 
cancer [32]. We compared the results of the pre-
sented case with the TCGA data. TCGA identified 
PIK3CA, the alpha catalytic subunit of PI3K, as the 
most common SMG in breast lumen cancer, oc-
curring at 45% and 29% rates in the lumen A and 
lumen B subtypes, respectively. Often these are mis-
sense mutations that are grouped in the helical do-
main and the kinase domain of PI3 kinase and are 
capable of causing cellular transformation when 
introduced into mammary epithelial cells [33].
The TP53 gene product is a potent tumor sup-
pressor that induces apoptosis or cell cycle arrest 
in response to cellular stress. A mutation in the 
TP53 gene is a characteristic feature of basal-like 
breast cancer. In ER+ breast cancer, TP53 muta-
tion is less common (30% in lumen B and 12% in 
lumen A) [34, 35].
conclusion
The national integrated cancer control network 
(NCCN) has established guidelines for testing 
BRCA mutations and for treating people who have 
a mutation in the BRCA1\2 genes. As our patient 
has the early age of developing the disease, fam-
ily history, we used the principles of this guide. 
NCCN has published recommendations for ob-
serving women with positive test for one of the 
BRCA mutations [31]. Guided by the principle 
of NCCN, we will observe the relatives of our 
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